Effect of the Known Antihypertensive Drug Telmisartan on Red Blood Cells and Circulation in the Smallest Blood Vessels

Arterial Hypertension Clinical Trial

— ITEM  

Official title:

Influence of the Angiotensin Receptor Blocker Telmisartan on the Red Blood Cell Function and the Microcirculatory Perfusion

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00559286
• Other study ID #: AIX-MK-01
• Secondary ID: EUDRA CT No 2007
• Status: Terminated
• Phase: Phase 4
• First received: November 15, 2007
• Last updated: January 28, 2009
• Start date: December 2007
• Est. completion date: January 2009

Study information

• Verified date: January 2009
• Source: RWTH Aachen University
• Contact: n/a
• Is FDA regulated: No
• Health authority: Germany: Federal Institute for Drugs and Medical Devices
• Study type: Interventional

Clinical Trial Summary

The hypothesis of the presented study is: Telmisartan induces an increase of eNOS activity in RBC resulting in an enhanced intravascular NO bioavailability, an ameliorated RBC deformability and a reduction of RBC and platelet aggregation. This could be a potential mechanism of the improvement of microcirculatory disorders, especially in patients with diabetes mellitus and arterial hypertension, treated with Telmisartan.

Description:

Recently, it could be shown that the renin-angiotensin-system (RAS) influences different signal transduction pathways within the red blood cells (RBC). This includes the Na+/H+ exchange activity, the Ca2+-ATP-ase mediated Ca2+efflux, the erythropoietin- dependent production of RBC, the RBC deformability, RBC aggregation and the interaction of RBC and platelets. Recent studies and experiments, done by our group, focus on the oxidative and nitrosative metabolism of NO within the blood. The interactions of the RAS and endothelial NO are well known and described in detail. Based on a wide experience in this research field of NO metabolism, we characterized recently an active endothelial-type NO-synthase in RBC on the biochemical, functional and molecular level. Erythrocyte-derived NO formation serves important regulatory functions essential for adequate passage of blood through the vasculature. Here we aimed to treat patients with diabetes mellitus and arterial hypertension with Telmisartan as an angiotensin receptor antagonist. Efficacy parameters studied in this study should be: i) RBC deformability, RBC aggregation, ii) RBC dependent production of nitric oxide as well as detection of eNOS activity in RBC and iii) indices of microcirculatory perfusion. This project could broaden the view of effects of Telmisartan in the treatment of microcirculatory disorders in patients with diabetes mellitus and arterial hypertension, who exhibit a reduced NO bioavailability and RBC function.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 40
• Est. completion date: January 2009
• Est. primary completion date: January 2009
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Men older than 18 years

• Diabetes mellitus type 2 defined according to the criteria of the American Diabetes Association Arterial hypertension defined according to the criteria of the Joint National Committtees (JNC 7)

• Given informed consent

Exclusion Criteria:

• Serve heart failure

• Serve aortic valve stenosis or hypertrophy obstructive cardiomyopathy

• Relevant cardiac arrhythmias

• Acute myocardial infarction within the last 4 weeks

• renal failure

• bilateral renal artery stenosis

• liver diseases

• primary hyperaldosteronism

• orthostatic hypotension (systolic blood pressure <100mmHg)

• hypokalemia, hyponatremia, hypercalcemia, symptomatic hyperuricemia

• inflammatory disease

• malignant disease

• previous intolerance to AT1 receptor antagonists and/or sulfonamides

• current therapy with insulin sensitizer

• current therapy with digoxin

• known abuse of alcohol or drugs

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Arterial Hypertension
• Diabetes Mellitus Type 2 IRC or NIR
• Diabetes Mellitus, Type 2
• Hypertension

Intervention

Drug:
• Telmisartan
application of 80mg or 20mg Telmisartan per day for 30 days

Locations

Country	Name	City	State
Germany	University Hospital	Aachen	NRW

Sponsors (4)

Lead Sponsor	Collaborator
RWTH Aachen University	Bayer, CTCA, Heidelberg University

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Changes in Elongation-Index (EI) Method: To determine the elongation index (EI) we use the Laser assisted optical rotational cell analyzer (Lorrca).		after 30 days of treatment with study drug/control
Secondary	Improvement of microcirculatory perfusion (using laser doppler measurement)		after 30 days treatment
Secondary	Improvement of endothelial function (using ultrasound measurements during flow mediated dilation)		after 30 days treatment
Secondary	Increase in the total blood born NO pool (using reductive gase phase chemiluminescence		after 30 days treatment
Secondary	Decrease of RBC aggregation (using Laser assisted optical rotational cell analyzer (Lorrca)		after 30 days of treatment